Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) insider James Patrick Tursi acquired 4,750 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were purchased at an average cost of $2.11 per share, for a total transaction of $10,022.50. Following the completion of the acquisition, the insider now directly owns 184,118 shares in the company, valued at $388,488.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) traded up 4.89% during midday trading on Monday, hitting $2.36. The stock had a trading volume of 4,483,632 shares. The firm has a 50 day moving average of $3.88 and a 200 day moving average of $4.58. Aralez Pharmaceuticals Inc has a 52 week low of $2.05 and a 52 week high of $6.80. The firm’s market cap is $154.58 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Monday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.11. The firm earned $20 million during the quarter, compared to the consensus estimate of $21.86 million. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. Aralez Pharmaceuticals’s revenue for the quarter was up 233.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.40) EPS. Equities research analysts predict that Aralez Pharmaceuticals Inc will post ($1.07) EPS for the current year.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Your IP Address:

Separately, Chardan Capital lowered their target price on Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, March 15th.

A number of institutional investors have recently bought and sold shares of the company. Armistice Capital LLC increased its position in Aralez Pharmaceuticals by 35.0% in the fourth quarter. Armistice Capital LLC now owns 2,836,000 shares of the company’s stock worth $12,507,000 after buying an additional 736,000 shares during the period. Broadfin Capital LLC increased its position in Aralez Pharmaceuticals by 8.7% in the fourth quarter. Broadfin Capital LLC now owns 4,791,590 shares of the company’s stock worth $21,131,000 after buying an additional 384,600 shares during the period. Drill Craig A increased its position in Aralez Pharmaceuticals by 64.0% in the third quarter. Drill Craig A now owns 958,945 shares of the company’s stock worth $4,651,000 after buying an additional 374,345 shares during the period. Norges Bank purchased a new position in Aralez Pharmaceuticals during the fourth quarter worth about $665,000. Finally, Advisor Group Inc. increased its position in Aralez Pharmaceuticals by 218.2% in the third quarter. Advisor Group Inc. now owns 115,184 shares of the company’s stock worth $559,000 after buying an additional 78,984 shares during the period. Institutional investors and hedge funds own 44.01% of the company’s stock.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.